



ASX Release

23 June, 2006

Dia-B advances research on anti-diabetes compound

Melbourne biotech group Dia-B expects to begin clinical trials of its ISF402 anti-diabetes compound in the last quarter of 2006 after initial trials on animals proved that the compound is effective in lowering blood glucose levels.

This milestone now allows the Company to prepare the appropriate protocols and documentation for regulatory approvals to commence Phase 1 human trials after the completion of mandatory animal toxicity studies to be completed during August, said Dia-B Chairman Dr Michael Wooldridge.

“Dia-B is excited with the progress of ISF402 as an oral drug that can enhance insulin action to reduce glucose in the blood stream of the body, and to potentially benefit type 2 diabetes sufferers world wide,” he said.

“Initial animal sighting studies showed no toxicity, and Dia-B is confident that ISF402 will be ready for human trials in the final quarter.”

Recently completed animal studies on rabbits have shown that ISF402 works when delivered orally. This is in addition to prior work that confirmed the success of lowering blood glucose when ISF402 was given orally to rats. The effective dose in rabbits was 4-fold lower than in rats.

“It is significant to have the same results achieved from two animal species,” said Dia-B Chairman Dr Michael Wooldridge.

ends-

For more information, please contact:

Ken Smith, CEO

Dia-B Tech Limited

ACN 102 456 048

Tel: +61 3 8862 6319

Fax: +61 3 8862 6610

Mob: 0412 190 908

www.dia-btech.com.au